Literature DB >> 25394182

Atlas stumbled: kinesin light chain-1 variant E triggers a vicious cycle of axonal transport disruption and amyloid-β generation in Alzheimer's disease.

Kathlyn J Gan1, Takashi Morihara, Michael A Silverman.   

Abstract

Substantial evidence implicates fast axonal transport (FAT) defects in neurodegeneration. In Alzheimer's disease (AD), it is controversial whether transport defects cause or arise from amyloid-β (Aβ)-induced toxicity. Using a novel, unbiased genetic screen, Morihara et al. identified kinesin light chain-1 splice variant E (KLC1vE) as a modifier of Aβ accumulation. Here, we propose three mechanisms to explain this causal role. First, KLC1vE reduces APP transport, leading to Aβ accumulation. Second, reduced transport of APP by KLC1vE triggers an ER stress response that activates the amyloidogenic pathway. Third, KLC1vE impairs transport of other KLC1 cargos that regulate amyloidogenesis, promoting Aβ retention within the secretory pathway. Collectively, KLC1vE perpetuates a vicious cycle of Aβ generation, kinase dysregulation, and global FAT impairment that inevitably leads to cellular toxicity. These concepts implicate alternative splicing of KLC1 in AD and suggest that the reciprocal influence of transport mechanisms on disease states contributes to neurodegeneration.
© 2015 WILEY Periodicals, Inc.

Entities:  

Keywords:  Alzheimer's disease; alternative splicing; amyloid precursor protein; amyloid-β; axonal transport; kinesin; kinesin light chain

Mesh:

Substances:

Year:  2014        PMID: 25394182     DOI: 10.1002/bies.201400131

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  8 in total

1.  Kinesin light chain-1 variant E disrupts axonal transport and Aβ generation in Alzheimer's disease (comment on DOI 10.1002/bies.201400131).

Authors:  Huntington Potter
Journal:  Bioessays       Date:  2015-01-12       Impact factor: 4.345

Review 2.  Amyloid-β precursor protein: Multiple fragments, numerous transport routes and mechanisms.

Authors:  Virgil Muresan; Zoia Ladescu Muresan
Journal:  Exp Cell Res       Date:  2015-01-06       Impact factor: 3.905

Review 3.  Mechanisms of Mitochondrial Malfunction in Alzheimer's Disease: New Therapeutic Hope.

Authors:  Showkat Ul Nabi; Andleeb Khan; Ehraz Mehmood Siddiqui; Muneeb U Rehman; Saeed Alshahrani; Azher Arafah; Sidharth Mehan; Rana M Alsaffar; Athanasios Alexiou; Bairong Shen
Journal:  Oxid Med Cell Longev       Date:  2022-05-14       Impact factor: 7.310

Review 4.  Microtubules in health and degenerative disease of the nervous system.

Authors:  Andrew J Matamoros; Peter W Baas
Journal:  Brain Res Bull       Date:  2016-06-27       Impact factor: 4.077

5.  New Insights into Epigenetic and Pharmacological Regulation of Amyloid-Degrading Enzymes.

Authors:  Natalia N Nalivaeva; Nikolai D Belyaev; Anthony J Turner
Journal:  Neurochem Res       Date:  2015-09-16       Impact factor: 3.996

6.  Exogenous brain-derived neurotrophic factor attenuates cognitive impairment induced by okadaic acid in a rat model of Alzheimer's disease.

Authors:  Ai-Hua Xu; Yang Yang; Yong-Xin Sun; Chao-Dong Zhang
Journal:  Neural Regen Res       Date:  2018-12       Impact factor: 5.135

7.  Vaccinia virus protein complex F12/E2 interacts with kinesin light chain isoform 2 to engage the kinesin-1 motor complex.

Authors:  David C J Carpentier; William N D Gao; Helen Ewles; Gareth W Morgan; Geoffrey L Smith
Journal:  PLoS Pathog       Date:  2015-03-11       Impact factor: 6.823

8.  Integrated analysis of human genetic association study and mouse transcriptome suggests LBH and SHF genes as novel susceptible genes for amyloid-β accumulation in Alzheimer's disease.

Authors:  Yumi Yamaguchi-Kabata; Takashi Morihara; Tomoyuki Ohara; Toshiharu Ninomiya; Atsushi Takahashi; Hiroyasu Akatsu; Yoshio Hashizume; Noriyuki Hayashi; Daichi Shigemizu; Keith A Boroevich; Manabu Ikeda; Michiaki Kubo; Masatoshi Takeda; Tatsuhiko Tsunoda
Journal:  Hum Genet       Date:  2018-07-13       Impact factor: 4.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.